In July 2023, we changed our name from AACC (short for the American Association for Clinical Chemistry) to the Association for Diagnostics & Laboratory Medicine (ADLM). The following page links to resources that were written prior to the rebranding and/or mentions events that took place prior to the rebranding and that contain mentions of the association’s old name.
Day two of AACC’s first-ever virtual meeting, “Personalized Diagnostics Today: Where the Omics Community Collaborates” will open with an insightful look at the role of precision proteomics in personalized medicine. Plenary speaker Henry Rodriguez, PhD, MBA, who is director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), will pull back the curtain on NCI's consortium of research centers, which are focusing on identifying proteins that derive from cancer genomes. He also will examine advantages of targeted mass spectrometry protein-based multiplexed tests over conventional clinical tests, and the regulatory processes in validating an in vitro diagnostic multiplexed mass spectrometry assay.
“The natural continuum from genomics to proteomics is giving rise to a new inter-discipline called proteogenomics that complements genome and transcriptome information, and is positioned to generate advances in biomedical research, creating opportunities for clinical laboratories,” says Rodriguez. “Targeted mass spectrometric approaches over the last five years have shown their tremendous potential in clinical proteomics. Adoption of targeted MS to study clinical questions is well underway as these assays provide higher specificity, sensitivity and a short development time.” Targeted MS can also mean potential savings in a large-volume environment, since it allows for multiplexing analytes, he adds.
Rodriguez, who is serving on the nine-member planning committee for Personalized Diagnostics Today, brings an impressive mix of education and professional experience to the meeting. A recognized leader in cancer research, Food and Drug Administration regulatory affairs, and government policy, he is responsible for providing authoritative leadership, including policy development on innovative technology initiatives that address NCI's expanding role in biomedical research, and the emerging field of proteogenomics.
Rodriguez’s plenary session will be followed by four concurrent sessions, two in the morning and two in the afternoon, addressing themes of: taking MS-MS assays from research to application in personalized medicine; using sequencing technologies in personalized diagnostics; new approaches in proteomics and metabolomics; and the perspective of personal diagnostics exhibitors. Rodriguez will round out the day as part of a panel on taking biomarkers from discovery to practice.
This virtual meeting will take place in 12 sessions over two days, October 28-29, and offers up to 21 continuing education credits. It is free for AACC members and available to non-AACC members at an attractive rate. Register to attend the meeting online.